Morgan Stanley Downgrades Teva Pharma to Hold

By Austin Angelo

In a report released today, David Risinger from Morgan Stanley downgraded Teva Pharma (NYSE: TEVA) to Hold, with a price target of $42. The company’s shares closed yesterday at $37.60, close to its 52-week low of $37.25.

According to TipRanks.com, Risinger is ranked 0 out of 5 stars with an average return of -7.9% and a 40.4% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, Horizon Pharma Inc., and Endo International.

Currently, the analyst consensus on Teva Pharma is Moderate Buy and the average price target is $64, representing a 70.2% upside.

In a report issued on November 4, HSBC also downgraded the stock to Hold with a $44 price target.

The company has a one year high of $66.55 and a one year low of $37.25. Currently, Teva Pharma has an average volume of 8.67M.

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine. The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment includes several franchises, most significantly core therapeutic areas of CNS medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.